Quick Answer
Neurogene Inc. reported Cash and Equivalents of $103.84 million for fiscal year 2025.
Neurogene Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $103.84M | -24.0% |
| 2024 | $136.59M | -7.8% |
| 2023 | $148.21M | +80.7% |
| 2022 | $82.02M | -42.4% |
| 2021 | $142.47M | -26.0% |
| 2020 | $192.56M | +34.6% |
| 2019 | $143.09M | +86.0% |
| 2018 | $76.93M | +47.8% |
| 2017 | $52.03M | +61.1% |
| 2016 | $32.30M | -18.3% |
| 2015 | $39.53M | +165.2% |
| 2014 | $14.91M | +35.4% |
| 2013 | $11.01M | +450.0% |
| 2012 | $2.00M | -78.3% |
| 2011 | $9.24M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $71.00M | +6.6% | +20.7% |
| June 30, 2025 | $58.81M | -47.0% | -16.9% |
| March 31, 2025 | $70.77M | -52.9% | -48.2% |
| December 31, 2024 | $136.59M | -7.8% | +105.0% |
| September 30, 2024 | $66.63M | +164.1% | -40.0% |
| June 30, 2024 | $111.03M | +256.9% | -26.0% |
| March 31, 2024 | $150.14M | +323.0% | +1.3% |
| December 31, 2023 | $148.21M | +291.2% | +487.5% |
- Neurogene Inc. showed a decrease of -24.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2011–2025 period, Neurogene Inc.’s cash and equivalents has grown by 1024.0% (from $9.24 million to $103.84 million).
- The most recent figure is from Neurogene Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: